This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, C.-C.
Right arrow Articles by Yeh, L.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.-C.
Right arrow Articles by Yeh, L.-T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1872-1875, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1872-1875.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Disposition and Metabolic Profiles of [14C]Viramidine and [14C]Ribavirin in Rat and Monkey Red Blood Cells and Liver

Chin-Chung Lin,* David Lourenco, Guifen Xu, and Li-Tain Yeh

Research and Development, Valeant Pharmaceuticals International, Costa Mesa, California 92626

Received 21 October 2003/ Returned for modification 18 December 2003/ Accepted 21 January 2004

The disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin were compared in rat and monkey red blood cells and liver. Our data reveal that the total ribavirin-related components (ribavirin plus its mono-, di-, and triphosphate metabolites) may account for most of the drug in monkey liver following prolonged oral administration of viramidine.

* Corresponding author. Mailing address: Valeant Pharmaceuticals International, 3300 Hyland Ave., Costa Mesa, CA 92626. Phone: (714) 545-0100, ext. 2062, Fax: (714) 641-7201. E-mail: cclin{at}valeant.com.

Antimicrobial Agents and Chemotherapy, May 2004, p. 1872-1875, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1872-1875.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Michaelis, M., Michaelis, R., Suhan, T., Schmidt, H., Mohamed, A., Doerr, H. W., Cinatl, J. Jr. (2007). Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion. FASEB J. 21: 81-87 [Abstract] [Full Text]  
  • Lin, C.-c., Xu, C., Zhu, N., Yeh, L.-T. (2006). Absorption, Metabolism, and Excretion of [14C]Viramidine in Humans.. Antimicrob. Agents Chemother. 50: 2368-2373 [Abstract] [Full Text]  
  • Wu, J. Z., Larson, G., Walker, H., Shim, J. H., Hong, Z. (2005). Phosphorylation of Ribavirin and Viramidine by Adenosine Kinase and Cytosolic 5'-Nucleotidase II: Implications for Ribavirin Metabolism in Erythrocytes. Antimicrob. Agents Chemother. 49: 2164-2171 [Abstract] [Full Text]  
  • Wu, J. Z., Larson, G., Hong, Z. (2004). Dual-Action Mechanism of Viramidine Functioning as a Prodrug and as a Catabolic Inhibitor for Ribavirin. Antimicrob. Agents Chemother. 48: 4006-4008 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»